Global Swine Epidemic Diarrhea Vaccines Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Swine Epidemic Diarrhea Vaccines Market Insights, Forecast to 2034
Swine epidemic diarrhea virus (PEDV) is the causative agent of porcine epidemic diarrhea (PED), an acute and highly contagious enteric viral disease.
Market Analysis and InsightsGlobal Swine Epidemic Diarrhea Vaccines Market
Global Swine Epidemic Diarrhea Vaccines market is expected to reach to US$ 1423 million in 2024, with a positive growth of %, compared with US$ 1354 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Swine Epidemic Diarrhea Vaccines industry is evaluated to reach US$ 1907 million in 2029. The CAGR will be 5.0% during 2024 to 2029.
The Animal Healthcare market is primarily driven by the increasing awareness about animal health and well-being, coupled with the rising prevalence of various animal diseases. Pet ownership has grown, leading to higher demand for veterinary services and products. Additionally, the growth of the livestock industry to meet global food demand further boosts the need for animal healthcare products. Advances in veterinary medicine and technology are also driving market growth, enabling better diagnosis, treatment, and preventive care for animals. However, challenges include regulatory complexities and the high cost of certain treatments, which can hinder accessibility for some pet owners or farmers. Striking a balance between quality care and affordability is crucial for the sustainable growth of the animal healthcare market.
Report Covers
This report presents an overview of global Swine Epidemic Diarrhea Vaccines market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Swine Epidemic Diarrhea Vaccines market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
CAVAC
Green Cross Veterinary Products
Harrisvaccines, Inc.
Komipharm
Nisseiken
Qilu Animal Health
Zoetis
Segment by Type
Live Vaccines
Killed Vaccines
Piglets
Adults Pigs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Swine Epidemic Diarrhea Vaccines introduction, etc. Swine Epidemic Diarrhea Vaccines Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Swine Epidemic Diarrhea Vaccines
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Swine Epidemic Diarrhea Vaccines Market
Global Swine Epidemic Diarrhea Vaccines market is expected to reach to US$ 1423 million in 2024, with a positive growth of %, compared with US$ 1354 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Swine Epidemic Diarrhea Vaccines industry is evaluated to reach US$ 1907 million in 2029. The CAGR will be 5.0% during 2024 to 2029.
The Animal Healthcare market is primarily driven by the increasing awareness about animal health and well-being, coupled with the rising prevalence of various animal diseases. Pet ownership has grown, leading to higher demand for veterinary services and products. Additionally, the growth of the livestock industry to meet global food demand further boosts the need for animal healthcare products. Advances in veterinary medicine and technology are also driving market growth, enabling better diagnosis, treatment, and preventive care for animals. However, challenges include regulatory complexities and the high cost of certain treatments, which can hinder accessibility for some pet owners or farmers. Striking a balance between quality care and affordability is crucial for the sustainable growth of the animal healthcare market.
Report Covers
This report presents an overview of global Swine Epidemic Diarrhea Vaccines market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Swine Epidemic Diarrhea Vaccines market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
CAVAC
Green Cross Veterinary Products
Harrisvaccines, Inc.
Komipharm
Nisseiken
Qilu Animal Health
Zoetis
Segment by Type
Live Vaccines
Killed Vaccines
Segment by Application
Piglets
Adults Pigs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Swine Epidemic Diarrhea Vaccines introduction, etc. Swine Epidemic Diarrhea Vaccines Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Swine Epidemic Diarrhea Vaccines
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices